Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
Read original at benzingaStocks · News reference
OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est
OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 8:22 PM
- Checked
- Aug 12, 2026, 8:22 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
OptimizeRx Announces Appointment Of Andy D'Silva As CFO Effective January 1, 2027
Read original at benzingaOptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24 per share from the
Read original at benzinga